• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个辅助做出乳腺癌辅助治疗决策的计算机程序。

A computer program to assist in making breast cancer adjuvant therapy decisions.

作者信息

Ravdin P M

机构信息

Division of Oncology, University of Texas Health Sciences Center, San Antonio, 78284, USA.

出版信息

Semin Oncol. 1996 Feb;23(1 Suppl 2):43-50.

PMID:8614844
Abstract

This report describes a computer program designed to assist health care professionals in making projections of the average benefit of systemic adjuvant therapy for individual breast cancer patients. It requires as input patient age (used to make projections of natural mortality), an estimate of breast cancer-related mortality at 5 years (used to make projections of breast cancer-specific mortality), and the proportional risk reduction for breast cancer mortality expected for the adjuvant therapy (with included tables from the Early Breast Cancer Trialist's 1992 meta-analysis). The program uses life table analytical techniques to make projections of outcome in three scenarios: that the breast cancer never occurred, that the breast cancer patient received definitive local therapy but no adjuvant systemic therapy, and that the patient received adjuvant therapy. The outcome projections are given for total, natural (non-breast cancer-related), and breast cancer-related mortality at several time points and also of total remaining life expectancy. These estimates are currently widely made by clinicians by nonnumerical techniques. Computer-based tools can serve as valuable aids in physician and patient education and in the process of informed decision making.

摘要

本报告描述了一个计算机程序,该程序旨在协助医疗保健专业人员预测个体乳腺癌患者全身辅助治疗的平均获益情况。它需要输入患者年龄(用于预测自然死亡率)、5年时乳腺癌相关死亡率的估计值(用于预测乳腺癌特异性死亡率)以及辅助治疗预期的乳腺癌死亡率成比例降低值(包括1992年早期乳腺癌试验者荟萃分析中的表格)。该程序使用生命表分析技术在三种情况下预测结果:乳腺癌从未发生、乳腺癌患者接受了确定性局部治疗但未接受辅助全身治疗、患者接受了辅助治疗。给出了几个时间点的总死亡率、自然(与乳腺癌无关)死亡率和乳腺癌相关死亡率以及总剩余预期寿命的结果预测。目前临床医生广泛使用非数值技术进行这些估计。基于计算机的工具可作为医生和患者教育以及知情决策过程中的宝贵辅助工具。

相似文献

1
A computer program to assist in making breast cancer adjuvant therapy decisions.一个辅助做出乳腺癌辅助治疗决策的计算机程序。
Semin Oncol. 1996 Feb;23(1 Suppl 2):43-50.
2
A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients.一种基于计算机的程序,用于辅助个体乳腺癌患者的辅助治疗决策。
Bull Cancer. 1995 Dec;82 Suppl 5:561s-564s.
3
Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.T1a、bN0M0期乳腺癌患者的总生存期和特定病因死亡率。
J Clin Oncol. 2007 Nov 1;25(31):4952-60. doi: 10.1200/JCO.2006.08.0499.
4
A decision aid to assist in adjuvant therapy choices for breast cancer.一种辅助乳腺癌辅助治疗方案选择的决策辅助工具。
Psychooncology. 2006 Nov;15(11):1001-13. doi: 10.1002/pon.1040.
5
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.利用雌激素受体信息在美国推广乳腺癌辅助多药化疗和他莫昔芬:1975 - 1999年
J Natl Cancer Inst Monogr. 2006(36):7-15. doi: 10.1093/jncimonographs/lgj003.
6
Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?辅助治疗对老年淋巴结阳性早期乳腺癌患者是否具有成本效益?
Breast Cancer Res Treat. 2005 Nov;94(2):95-103. doi: 10.1007/s10549-004-8267-0.
7
Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.老年女性乳腺癌手术后辅助化疗起始时间的延迟
Breast Cancer Res Treat. 2006 Oct;99(3):313-21. doi: 10.1007/s10549-006-9206-z. Epub 2006 Apr 1.
8
Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.瑞典东南部I期乳腺癌女性患者生存率提高:辅助性全身治疗使用增加前后两个时间段的比较
Acta Oncol. 2009;48(4):504-13. doi: 10.1080/02841860902718754.
9
Adjuvant therapy for breast cancer.乳腺癌辅助治疗
NIH Consens Statement. 2000;17(4):1-35.
10
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.阿那曲唑与他莫昔芬作为早期雌激素受体阳性乳腺癌患者初始辅助治疗的获益及预期成本效益
Cancer. 2004 Sep 15;101(6):1311-22. doi: 10.1002/cncr.20492.

引用本文的文献

1
Molecular Biology in the Breast Clinics-Current status and future perspectives.乳腺诊所中的分子生物学——现状与未来展望
Indian J Surg Oncol. 2021 Apr;12(Suppl 1):7-20. doi: 10.1007/s13193-019-00954-1. Epub 2019 Aug 10.
2
Nomogram Identifies Age as the Most Important Predictor of Overall Survival in Oral Cavity Squamous Cell Cancer After Primary Surgery.列线图确定年龄是口腔鳞状细胞癌初次手术后总生存的最重要预测因素。
Indian J Otolaryngol Head Neck Surg. 2020 Jun;72(2):160-168. doi: 10.1007/s12070-019-01726-7. Epub 2019 Aug 16.
3
Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer?
在雌激素受体阳性乳腺癌的系统治疗背景下,在线预测工具能否有效替代基因谱分析?
Cell Mol Biol Lett. 2017 Sep 4;22:20. doi: 10.1186/s11658-017-0049-x. eCollection 2017.
4
Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models.我们能够预测雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌的生存率吗?基于网络模型的比较。
Br J Cancer. 2015 Mar 3;112(5):912-7. doi: 10.1038/bjc.2014.641. Epub 2015 Jan 15.
5
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.预测 Oncotype DX 复发评分:使用通过线性回归分析得出的病理生成方程。
Mod Pathol. 2013 May;26(5):658-64. doi: 10.1038/modpathol.2013.36. Epub 2013 Mar 15.
6
External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.辅助!在线乳腺癌预后工具的外部验证。优先考虑改进建议。
PLoS One. 2011;6(11):e27446. doi: 10.1371/journal.pone.0027446. Epub 2011 Nov 8.
7
Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer.预测可切除胆囊癌辅助放化疗获益的列线图。
J Clin Oncol. 2011 Dec 10;29(35):4627-32. doi: 10.1200/JCO.2010.33.8020. Epub 2011 Nov 7.
8
Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?辅助! 模型的使用是否通过更好的风险沟通影响辅助治疗的使用?
J Natl Compr Canc Netw. 2011 Jul 1;9(7):707-12. doi: 10.6004/jnccn.2011.0061.
9
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.美国临床肿瘤学会临床实践指南:激素受体阳性乳腺癌患者辅助内分泌治疗的更新。
J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Epub 2010 Jul 12.
10
Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.肿瘤学家对辅助治疗!模型用于风险沟通的应用:一项检验患者对10年预后了解情况的试点研究。
BMC Cancer. 2009 Apr 28;9:127. doi: 10.1186/1471-2407-9-127.